Other studies coming out of Europe have also found SB4 to work well for the majority of patients who switched from the originator etanercept.
Samsung Bioepis’ etanercept biosimilar, SB4, was effective and well-tolerated in the majority of patients who switched from originator etanercept (Enrel), according to a study from Poland.
The biosimilar is approved in a variety of European markets under the name Benepali. While it was approved by the FDA in April 2019, it has not yet launched here due to patent litigation. The anti-tumor necrosis factor (anti-TNF) inhibitor is currently prescribed in the United States for rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), ankylosing spondylitis, and plaque psoriasis.
The observational study looked at patients being treated for RA, juvenile idiopathic arthritis, PsA, or ankylosing spondylitis, in which the originator etanercept replaced SB4.
Etanercept was replaced with SB4 in 162 patients (Group 1), and in another 6 patients SB4 was the initial biologic used (Group 2). Efficacy and safety were assessed over a 6-month period.
The biosimilar was effective and well-tolerated in the majority of patients. For 24 patients in Group 1 (14.8%), returning to Enbrel was necessary due to loss of efficacy or adverse events. Returning to the originator reversed the loss of efficacy or resolved the adverse event.
Previous observational studies have found rates of discontinuing the biosimilar ranging from 2% to 14%. In this study:
No adverse events were reported in the 6 patients for whom the biosimilar was the initial therapy (Group 2), and the biosimilar was effective in these patients.
Other studies coming out of Europe have also found SB4 to work well for the majority of patients who switched from the originator etanercept.
The authors conclude that SB4 was effective and well-tolerated in most patients, but that further research is required to investigate the effects of switching patients between originators and biosimilars.
Reference
Felis-Giemza A, Chmurzyńska K, Nałęcz-Janik J, et al. Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar. Reumatologia. 2019;57(5):257—263. doi:10.5114/reum.2019.89516.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen